上海医药：预计2025年上半年净利润同比增长约52%

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) expects a net profit of 4.45 billion yuan for the first half of 2025, representing a year-on-year increase of approximately 52% due to the acquisition of a 10% stake in Yangtze Pharmaceutical [1] Financial Performance - The anticipated net profit for the first half of 2025 is 4.45 billion yuan, an increase of 1.508 billion yuan compared to the same period last year [1] - The growth in profit is primarily attributed to the completion of the acquisition of Yangtze Pharmaceutical in April 2025, which will be included in the consolidated financial statements [1]